Notice of Results

Alliance Pharma PLC
02 March 2006


For Immediate Release                                               2 March 2006



                              ALLIANCE PHARMA PLC
                         ('Alliance' or 'the Company')

                      Notification of Preliminary Results


On behalf of our client Alliance Pharma plc (AIM: APH), the emerging speciality
pharmaceutical company, we notify that they will be reporting their Preliminary
Results for the ten months ended 31 December, 2005 on Thursday 23 March, 2006.

As notified at the time of the Interims results in November last year, the
company has changed its year end from February to December to bring it into line
with its peer companies.



For further information:
Buchanan Communications                                    + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich




Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a
strong track record of acquiring the rights to established niche brands and
owns, or shares, the rights to 30 branded pharmaceutical products and continues
to explore opportunities to expand the range.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven.  Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.

Alliance Pharma is also developing novel products for sleep disorders and the
induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.




                      This information is provided by RNS
            The company news service from the London Stock Exchange